A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pembrolizumab (Primary) ; UV 1 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Ultimovacs AS
- 01 Oct 2019 According to an Ultimovacs AS media release, data were presented at the ESMO 2019.
- 01 Oct 2019 According to an Ultimovacs AS media release, all formal criteria are fulfilled to start the inclusion of 10 additional patients in this trial. Originally planned 20 patients have been enrolled. all patients are expected to recruited by early 2020.
- 21 Aug 2019 Planned number of patients changed from 20 to 30, according to an Ultimovacs AS media release.